MedTrace Logo

Beta-Cell Transplantation in Pre-Uremic Patients With Type 1 Diabetes

NCT00623610 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2008-02-26

No results posted yet for this study

Summary

To examine whether temporary immunosuppression with ATG, tacrolimus and MMF allows prolonged survival of beta cell allografts in type 1 diabetic patients with early chronic complications of diabetes.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

PROCEDURE

islet cell grafts

Intraportal injection of an islet cell graft into the liver.

Sponsors & Collaborators

  • Vrije Universiteit Brussel

    collaborator OTHER

  • Universitaire Ziekenhuizen KU Leuven

    collaborator OTHER

  • Universiteit Antwerpen

    collaborator OTHER

  • Erasme University Hospital

    collaborator OTHER

  • AZ-VUB

    lead OTHER

Principal Investigators

  • Bart Keymeulen, MD, PhD · Universitair Ziekenhuis Brussel

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-09-30
Primary Completion
2005-10-31
Completion
2005-10-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00623610 on ClinicalTrials.gov